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Type 1 diabetes (T1D) mellitus is widely con-
sidered to result from an autoimmune destruc-
tion of the insulin-producing pancreatic  cells 
(Tisch and McDevitt, 1996; Mathis et al., 2001; 
Knip and Siljander, 2008). Although the pres-
ence of several human leukocyte antigen 
genotypes indicate the importance of genetic 
predisposition to T1D (Horn et al., 1988; 
Sheehy et al., 1989; Hagopian et al., 2011; 
Vehik and Dabelea, 2011), and increasing evi-
dence points to environmental triggers and regu-
lators (Knip et al., 2005; Hober and Sauter, 
2010; Norris, 2010; Stene et al., 2010; Foxman 
and Iwasaki, 2011), the exact etiology of this 
disease remains unknown.
It has been estimated that only 20% of 
 cell mass remains at the clinical presentation 
of T1D (Knip and Siljander, 2008), which is 
typically preceded by an asymptomatic period 
of highly variable duration that can last for 
a few months or for decades (Knip, 2002). 
The appearance of one or more autoantibodies 
against islet cell antigens is among the first de-
tectable signs of emerging  cell autoimmunity 
(Knip et al., 2005). These autoantigens include 
glutamic acid decarboxylase (GAD), protein 
tyrosine phosphatase (IA-2), insulin, and, most 
recently, the zinc transporter Slc30A8 protein 
(Wenzlau et al., 2007). Multiple autoantibody 
positivities, and their persistence, are unequiv-
ocally related to the risk of progression to overt 
T1D, as noted in both family studies and surveys 
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Using global liquid chromatography-mass spectrometry (LC-MS)–based proteomics analyses, 
we identified 24 serum proteins that were significantly variant between those with type 1 
diabetes (T1D) and healthy controls. Functionally, these proteins represent innate immune 
responses, the activation cascade of complement, inflammatory responses, and blood  
coagulation. Targeted verification analyses were performed on 52 surrogate peptides  
representing these proteins, with serum samples from an antibody standardization program 
cohort of 100 healthy control and 50 type 1 diabetic subjects. 16 peptides were verified as 
having very good discriminating power, with areas under the receiver operating characteristic 
curve ≥0.8. Further validation with blinded serum samples from an independent cohort  
(10 healthy control and 10 type 1 diabetics) demonstrated that peptides from platelet 
basic protein and C1 inhibitor achieved both 100% sensitivity and 100% specificity for 
classification of samples. The disease specificity of these proteins was assessed using sera 
from 50 age-matched type 2 diabetic individuals, and a subset of proteins, C1 inhibitor  
in particular, were exceptionally good discriminators between these two forms of diabetes. 
The panel of biomarkers distinguishing those with T1D from healthy controls and those 
with type 2 diabetes suggests that dysregulated innate immune responses may be associ-
ated with the development of this disorder.
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we identified 24 proteins (Fig. 1) that demonstrated sig-
nificant changes (P < 0.05, Student’s t test) between type 1 
diabetic and healthy control samples, including 4 proteins 
(AZGP1, CLU, SERPINA6, and LUM) that showed sta-
tistically significant differences between T1D and healthy 
controls in a previous study (Metz et al., 2008). Functional 
annotation of these proteins showed that most are extra-
cellular proteins secreted from the liver, and have important 
roles in the innate immune response, complement activa-
tion cascade, inflammatory response, and blood coagulation. 
Collectively, these results implicate systemic dysregulations 
of general population cohorts (Mueller et al., 2002; Bingley 
et al., 2003; Barker et al., 2004; Siljander et al., 2007; Knip 
and Siljander, 2008). Although performance of autoantibody 
assays has improved considerably over the years, owing in 
large part to efforts by the Diabetes Antibody Standardization 
Program (DASP) and The Environmental Determinants of 
Diabetes in the Young consortium to standardize these assays 
(Bonifacio et al., 2010; Schlosser et al., 2010; Törn et al., 
2008), not all islet autoantibody-positive subjects progress to 
T1D (Bingley et al., 1997; Barker et al., 2004; Siljander et al., 
2007). In addition, the pathogenic role (if any) for islet auto-
antibodies in T1D remains elusive (Howson et al., 2011).
Therefore, we explored the potential of proteomics tech-
nologies for identifying novel biomarkers that could provide 
additional insight into the pathogenesis of T1D and whose 
measurement could be more accurate and precise for disease 
prediction and/or diagnosis than the currently available auto-
antibody measurements. We used liquid chromatography-
mass spectrometry (LC-MS)–based, bottom-up proteomics 
measurements to discover blood serum peptides/proteins that 
varied significantly between type 1 diabetic and control sub-
jects. These candidate peptide biomarkers were further veri-
fied using targeted, multiplexed multiple reaction monitoring 
(MRM) LC-MS assays (Anderson and Hunter, 2006; Kuzyk 
et al., 2009; Schiess et al., 2009) in a DASP sample cohort 
consisting of 100 healthy controls and 50 patient subjects. 
Using this approach, we identified a set of peptide biomark-
ers with above average ability to distinguish T1D from 
healthy controls, and these peptides were further validated in 
an independent 20-sample set blinded to the investigators. In 
addition, using serum samples from 50 age-matched type 2 
diabetes (T2D) individuals, these proteins were assessed for 
their specificity to hyperglycemia, the common physiological 
outcome shared between type 1 and T2D, with a panel of 
peptides identified to be specific only to T1D.
RESULTS
Discovery of T1D protein markers
For discovery of candidate protein markers of T1D, we pre-
pared 10 pooled sera from healthy control individuals and 
10 from individuals with T1D using samples of a DASP co-
hort; each pool was comprised of 5 subjects. To achieve 
broad proteomic coverage and to construct an accurate mass 
and time (AMT) tag reference database of identified peptides, 
intensive sample fractionation was performed at both the 
protein (to deplete the major serum proteins) and the peptide 
levels (to reduce the complexity of proteolytic digests before 
LC-MS analysis), in combination with high-throughput 
LC-MS/MS analyses. Subsequent label-free quantitative pro-
teomic measurements on tryptic digest of each pooled sera 
were performed using the LC-MS–based AMT tag approach 
(Zimmer et al., 2006; Metz et al., 2008). For these analyses, 
the samples were fractionated only at the protein level. LC-MS 
datasets were then analyzed using an established pipeline 
of software tools developed in house for AMT tag-based, 
bottom-up proteomics data (Kiebel et al., 2006). In the end, 
Figure 1. Candidate type 1 diabetes protein biomarkers discovered 
from LC-MS–based, bottom-up global proteomics experiments.  
10 pooled healthy control and 10 pooled T1D patient sera samples, with 
each pool comprised of sera aliquots from 5 individuals (total of 50 
healthy control and 50 type 1 diabetic individuals), were included in this 
global proteomics biomarker discovery study. Relative protein abundances 
(Z-score transformed) are displayed as their constituent relative peptide 
abundances. Only those proteins with >60% of their constitutive peptides 
passing a Student’s t test on the peptide level (P < 0.05) and followed in 
the targeted analyses are shown. Each row represents a unique peptide, 
and each column represents a pooled healthy control or type 1 diabetic 
patient sample. CP, healthy control pooled; PP, T1D patient pooled.
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determine their power in differentiating T1D from healthy 
controls. It should be noted that our analysis was based on all 
150 individuals without removing any outliers, as no further 
diagnostic or follow-up information was available on the 
anonymous DASP samples beyond the original sample desig-
nation, collection, and demographic information, despite the 
fact that there were samples clearly showing poor correlation 
within each sample group based on the partial least squares 
(PLS) and correlation analyses (Fig. 2).
The levels of 33 peptides were significantly different in 
type 1 diabetic subjects compared with healthy controls on 
the basis of the Mann-Whitney U test (P < 0.001), with 14 
peptides down-regulated by ≥1.5-fold and 6 peptides up- 
regulated by ≥1.5-fold in type 1 diabetic subjects (Table 1). 
Receiver operating characteristic (ROC) curve analysis was 
used to evaluate the performance of each peptide assay in 
discriminating type 1 diabetic from healthy control individu-
als. The areas under the curve (AUCs) with 95% confidence 
intervals showed that 16 of these 33 peptides had AUCs ≥0.8 
(Table 1). Four proteins were notable: complement C3, gelsolin 
(GSN), N-acetylmuramoyl-l-alanine amidase (PGLYRP2), 
and transthyretin (TTR); these proteins showed significant 
down-regulation among all of their 10 constitutive peptides. 
Importantly, the relative levels of down-regulation among 
peptides from the same proteins agree well with each other. 
Two proteins, platelet basic protein (PPBP) and plasma pro-
tease C1 inhibitor (SERPING1), showed significant up-reg-
ulation among the six surrogate peptides monitored, although 
the relative levels of up-regulation between the two peptides 
from PPBP did not agree well (see Discussion), with peptide 
NIQSLEVIGK having a dramatic up-regulation of 8.5-fold 
(P = 6.62E-18, U test) in the type 1 diabetic group. This 
peptide also had the highest AUC (0.93) in differentiating 
disease from control (Fig. 3). In addition, the cut-off values 
of relative peptide abundance corresponding to sensitivity at 
of pathogen clearance activities and imbalances in blood co-
agulation and humoral immune response in T1D.
Development of multiplexed peptide assays as surrogates  
of candidate protein markers
To significantly improve the accuracy, sensitivity, and speci-
ficity of peptide measurements, and to evaluate the utility of 
these candidate proteins as T1D markers in large cohorts, it is 
critical to select proteolytic peptides that can be used as sur-
rogates of these proteins. To this end, we used an iterative 
screening approach (Kuzyk et al., 2009) to select proteolytic 
peptides that have high detectability in tryptic digests of human 
serum and low interference from sample matrices, which re-
sulted in 52 peptides as surrogates for these 24 proteins in a 
multiplexed LC-MRM-MS assay (Table S1) on whole serum 
without depletion of major serum proteins. Quantification 
of these 52 peptides was assisted by spiking their custom- 
synthesized, stable isotope–labeled standard (SIS) peptide an-
alogues into tryptic digests of each individual serum sample. 
These SIS peptides co-elute, ionize, and fragment identically 
with their endogenous counterparts (Anderson and Hunter, 
2006; Kuzyk et al., 2009), and because the spiked amounts 
were individually adjusted to be close to the levels of their 
endogenous analogues (Kuzyk et al., 2009), abundances of 
the endogenous peptides and their corresponding proteins 
could be accurately measured based on the peak area ratios 
between endogenous and SIS peptides.
Verification of peptide markers in the DASP cohort
To minimize systematic errors during quantification of pep-
tides, we randomized the orders of both the sample proteo-
lytic digestion and LC-MRM-MS analysis. The measured 
abundances (the peak area ratios between endogenous pep-
tides and their SIS analogues) of these 52 peptides in each 
of the DASP cohort samples were statistically evaluated to 
Figure 2. Analysis of outlier samples in the verification DASP cohort (100 healthy control and 50 T1D subjects). Relative peptide abundances 
were used in the data analyses, which were calculated as the ratios between endogenous peptides and their spiked-in, heavy isotope–labeled synthetic 
analogues. PLS regression and correlation analyses were performed using DAnTE. (A) PLS scores plot showing the segregation of the two groups of  
samples, with red dots and blue dots representing healthy control and T1D patient samples, respectively. (B) Plot showing the Pearson correlation be-
tween each sample and all other samples in the cohort. The lighter the color, the better the correlation. The red and blue bars indicate healthy control and 
T1D patient samples, respectively.
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Table 1. Performance of candidate marker peptides in all study cohorts
Protein Peptide DASP Verification Cohort DASP Blind Validation Cohort T2D Specificity Cohort
FCa P-valuea AUC Specificity Sensitivity FCa P-valuea FCb P-valueb FCc P-valuec
AZGP1 EIPAWVPFDPAAQITK 1.2 2.43E-03 0.65 1 0 1.2 4.81E-01 1.3 4.75E-03 1.4 1.71E-04
BTD LSSGLVTAALYGR 1.1 5.59E-02 0.6 0.2 0.6 1.1 6.23E-01 1.2 2.63E-03 1.5 9.78E-07
BTD SHLIIAQVAK 1.1 7.19E-02 0.59 0.3 0.6 1.1 3.93E-01 1.3 2.69E-04 1.6 1.44E-07
C1R LFGEVTSPLFPK 1.6 4.58E-11 0.83 0.5 0.7 1.1 2.80E-01 1.5 3.36E-06 1.3 2.73E-03
C1R VSVHPDYR 1.1 2.45E-01 0.56 1 0 1.0 7.39E-01 1.3 5.72E-05 1.2 3.96E-03
C2 GESGGAVFLER 1.2 3.09E-02 0.61 0.2 0.9 1.1 2.47E-01 1.3 1.72E-03 1.7 2.53E-08
C2 HAIILLTDGK 1.0 7.60E-01 0.52 0 0.3 1.4 1.50E-03 1.4 1.01E-06 1.8 9.67E-11
C2 SSGQWQTPGATR 1.3 1.00E-01 0.58 1 0 1.4 5.20E-03 1.0 2.60E-01 1.4 1.09E-02
C3 DFDFVPPVVR 1.7 3.06E-11 0.83 0.1 1 1.2 5.79E-01 2.0 5.22E-11 1.6 3.75E-09
C3 TGLQEVEVK 1.7 1.81E-12 0.85 0.1 1 1.2 4.81E-01 1.8 4.34E-10 1.6 1.58E-08
C4A ITQVLHFTK 1.6 3.63E-10 0.81 0.3 1 1.1 9.71E-01 2.0 9.03E-10 1.7 6.73E-08
C6 ALNHLPLEYNSALYSR 1.4 2.43E-09 0.8 0.2 0.7 1.0 9.12E-01 1.7 2.93E-09 1.5 1.49E-07
CFP SISCQEIPGQQSR 1.6 2.44E-14 0.88 0.2 1 1.3 1.47E-02 1.7 1.58E-08 1.3 3.37E-04
CLU ELDESLQVAER 1.2 7.85E-05 0.7 0.3 0.8 1.1 4.81E-01 1.3 1.61E-05 1.2 7.01E-03
CLU LFDSDPITVTVPVEVSR 1.2 1.98E-02 0.62 1 0 1.3 2.80E-01 NM NM NM NM
CLU TLLSNLEEAK 1.3 8.17E-10 0.81 0.3 0.9 1.1 4.36E-01 1.3 1.11E-05 1.2 1.65E-03
CNDP1 ALEQDLPVNIK 1.2 3.67E-01 0.54 1 0.1 1.3 7.39E-01 1.6 6.01E-05 1.9 1.80E-06
CNDP1 EWVAIESDSVQPVPR 1.2 2.86E-01 0.55 0.9 0.2 1.2 1.00E+00 1.6 7.95E-04 1.7 9.28E-05
F2 ELLESYIDGR 1.3 5.44E-06 0.73 0.7 0.2 1.1 4.81E-01 1.2 4.39E-02 1.0 8.22E-01
F2 ETAASLLQAGYK 1.6 2.88E-10 0.82 0 1 1.2 8.92E-02 1.4 5.72E-05 1.1 1.51E-01
GPX3 QEPGENSEILPTLK 1.2 1.17E-04 0.69 1 0.2 1.1 2.47E-01 1.0 9.17E-01 1.1 5.75E-01
GPX3 YVRPGGGFVPNFQLFEK 1.3 5.33E-08 0.77 0.2 0.8 1.1 5.45E-01 1.0 5.79E-01 1.0 4.43E-01
GSN AGALNSNDAFVLK 1.4 9.64E-11 0.82 0.6 1 1.5 2.88E-03 1.1 1.38E-01 1.4 4.47E-05
GSN QTQVSVLPEGGETPLFK 1.4 9.76E-09 0.79 1 0.6 1.5 7.58E-05 1.1 2.28E-01 1.7 2.86E-07
GSN TGAQELLR 1.5 3.41E-09 0.8 0.3 1 1.4 2.88E-02 1.1 1.61E-01 1.3 1.59E-03
HGFAC EALVPLVADHK 1.2 5.35E-04 0.67 0.5 0 1.3 3.11E-02 1.0 6.90E-01 1.2 4.45E-02
HGFAC VANYVDWINDR 1.3 3.85E-03 0.64 0.9 0 1.1 6.84E-01 1.1 8.35E-01 1.0 7.91E-01
KLKB1 DSVTGTLPK 1.3 7.29E-06 0.73 0 1 1.1 4.36E-01 1.6 1.80E-06 1.7 6.66E-07
KLKB1 EIIIHQNYK 1.2 9.84E-04 0.67 0.3 0.4 1.2 7.53E-02 1.5 3.26E-06 1.6 5.57E-07
KLKB1 IAYGTQGSSGYSLR 1.1 4.76E-03 0.64 0.7 0.3 1.0 8.53E-01 1.6 1.27E-06 1.5 1.53E-05
KLKB1 IYSGILNLSDITK 1.1 4.89E-02 0.6 0.7 0.3 1.0 7.96E-01 1.6 3.15E-05 1.7 3.97E-06
KNG1 DIPTNSPELEETLTHTITK 1.2 2.68E-07 0.76 0.8 0.1 1.0 5.29E-01 1.5 3.75E-08 1.4 1.54E-07
KNG1 TVGSDTFYSFK 1.3 2.98E-07 0.76 0.2 1 1.0 6.84E-01 1.4 7.18E-08 1.4 2.23E-07
LUM FNALQYLR 1.0 2.67E-01 0.56 0.2 0.1 1.6 2.09E-03 1.0 4.56E-01 1.4 4.78E-04
LUM ISNIPDEYFK 1.0 1.03E-01 0.58 0.4 0.2 1.5 6.84E-03 1.1 5.60E-02 1.3 5.02E-03
LUM NNQIDHIDEK 1.0 6.65E-01 0.52 0.5 0.1 1.6 7.25E-04 1.1 7.83E-02 1.4 2.44E-03
PGLYRP2 AGLLRPDYALLGHR 1.5 8.33E-14 0.87 0.7 0.8 1.3 6.84E-03 1.4 5.84E-06 1.1 2.12E-01
PGLYRP2 PSLSHLLSQYYGAGVAR 1.5 1.77E-13 0.87 0.8 1 1.6 4.87E-04 1.4 1.11E-05 1.1 4.29E-01
PGLYRP2 TFTLLDPK 1.5 1.31E-11 0.84 0.8 0.9 1.4 6.84E-03 1.5 5.84E-06 1.1 2.46E-01
PPBP EESLDSDLYAELR 1.6 8.41E-08 0.77 0.3 1 1.6 4.93E-02 1.7 1.71E-04 11.0 4.44E-12
PPBP NIQSLEVIGK 8.5 6.62E-18 0.93 1 1 30.4 1.08E-05 1.2 7.44E-02 32.6 4.44E-12
SERPINA6 AQLLQGLGFNLTER 1.4 1.05E-06 0.75 1 0 1.3 2.88E-02 1.1 6.52E-01 1.1 5.95E-01
SERPINA6 EENFYVDETTVVK 1.1 1.00E-01 0.58 0.9 0.3 1.0 6.84E-01 1.1 4.51E-02 1.4 1.07E-06
SERPIND1 SVNDLYIQK 1.5 9.15E-11 0.83 0.3 0.8 1.2 1.65E-01 1.8 6.75E-10 1.5 4.56E-06
SERPIND1 TLEAQLTPR 1.5 1.17E-11 0.84 0.4 0.9 1.2 1.23E-01 1.8 7.00E-10 1.5 3.97E-06
SERPINF2 LGNQEPGGQTALK 1.0 6.96E-01 0.52 1 0 1.4 7.25E-04 -1.4 1.61E-05 1.7 5.55E-08
SERPING1 FQPTLLTLPR 2.6 1.71E-05 0.72 0.7 1 7.4 1.08E-05 7.5 5.66E-12 1.4 4.11E-03
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LC-MRM-MS–based assays and compared with that of the 
T1D and healthy control individuals in the DASP blind set. 
Except for the constituent peptides of proteins GPX3, GSN, 
HGFAC, LUM, SERPINA6, and TTR, where there is no 
significant variance (P > 0.01, U test) between type 1 and 
T2D, our results clearly showed that 21 peptides have an in-
creased ability (P < 0.001, U test; absolute fold change ≥ 1.5) 
to distinguish between these two types of diabetes (Table 1). 
These peptides are from proteins (C3, C4A, C6, CFP, 
KLKB1, KNG1, PGLYRP2, SERPIND1, and SERPING1) 
that are involved in complement activation, blood coagula-
tion, and the innate immune and inflammation responses. Nota-
bly, peptides from C1 inhibitor had significant up-regulation 
in T1D, but were down-regulated in T2D compared with 
healthy controls (Fig. 5). In addition, 22 peptides were also 
identified as having increased ability (as previously defined) to 
distinguish between T2D and healthy controls (Table 1), and 
these peptides could be used as markers for T2D. Importantly, 
the levels of the best performing peptides do not appear to 
correlate with the levels of HbA1c, which is the current best 
marker for average hyperglycemia (Fig. 6).
DISCUSSION
The inference of parent protein abundance based on constit-
uent peptide abundance is a key general challenge in bottom-
up proteomics (Nesvizhskii and Aebersold, 2005), especially 
in respect to human blood samples, where very complex al-
ternate splicing, in vivo proteolytic processing, and posttrans-
lational modifications occur on protein precursors. We used 
BLAST to ensure that each of the 52 peptides selected in our 
study were unique to only one gene name. The calculations 
of protein concentrations based on SIS peptides in general 
agree with the literature survey (Hortin et al., 2008) or with 
similar MRM types of protein concentration measurement 
(Kuzyk et al., 2009). Our results also showed that peptides 
belonging to the same protein had similar abundances, except 
for the platelet basic protein, as previously noted.
90% specificity (AS90) were obtained from the ROC sensitiv-
ity and specificity analyses (Bingley et al., 2003) for each pep-
tide, and this value was used as a threshold to classify the blind 
samples into control and type 1 diabetic individuals.
Utility of peptide markers in diagnosing T1D
An independent DASP cohort, composed of sera from 20 
individuals and blinded to the investigators, was measured 
using the aforementioned multiplexed LC-MRM-MS pep-
tide assay to evaluate the utility of these 52 peptide assays in 
diagnosing T1D. After sample unblinding, the sensitivity for 
each peptide assay was calculated as the percentage of type 1 
diabetic sera reported as positive using the cut-off value at 
AS90, and the specificity was calculated as the percentage of 
control sera reported as negative using the same threshold. 
Using this approach, we found 7 peptides from 4 (PGLYRP2, 
PPBP, SERPING1, and TTR) of the aforementioned pro-
teins showed both sensitivity and specificity >80% (Table 1). 
Importantly, two peptides, NIQSLEVIGK and LLDSLPS-
DTR, achieved both 100% sensitivity and 100% specific-
ity (Fig. 4). As shown in Fig. 4, if the cut-off values were 
slightly adjusted, then two more peptides (FQPTLLTLPR 
and TNLESILSYPK) would also have achieved 100% sensi-
tivity and 100% specificity. For the peptides that were up-
regulated in the type 1 diabetic subjects from this blinded 
cohort, NIQSLEVIGK showed a dramatic increase of 30.4-
fold (P = 1.08E-5, U test), whereas 3 peptides in C1 inhibitor 
protein (SERPING1) all had a fold change of greater than 
sevenfold (P = 1.08E-5, U test).
Differentiation of T1D from hyperglycemia caused by T2D
Hyperglycemia is the common clinical outcome among 
all types of diabetes mellitus. To establish the specificity 
of these peptide markers to T1D (i.e., instead of diabetes- 
associated hyperglycemia in general), abundances of these 
peptide markers in serum samples of 50 age-matched (Table 2) 
T2D individuals were measured using our established 
Protein Peptide DASP Verification Cohort DASP Blind Validation Cohort T2D Specificity Cohort
FCa P-valuea AUC Specificity Sensitivity FCa P-valuea FCb P-valueb FCc P-valuec
SERPING1 LLDSLPSDTR 2.1 1.39E-04 0.69 1 1 7.5 1.08E-05 7.2 9.20E-12 1.4 4.11E-03
SERPING1 LVLLNAIYLSAK 1.6 6.16E-03 0.64 0.7 1 3.3 2.06E-04 7.0 1.08E-11 1.4 4.42E-03
SERPING1 TNLESILSYPK 2.2 2.49E-05 0.71 0.8 1 7.1 1.08E-05 2.6 9.97E-12 1.0 8.04E-01
TTR AADDTWEPFASGK 1.7 3.11E-04 0.68 1 0.8 1.4 1.50E-03 1.1 6.65E-01 3.0 2.39E-11
TTR GSPAINVAVHVFR 1.7 5.35E-04 0.67 1 0.8 1.2 1.50E-03 1.2 1.62E-01 2.8 4.47E-11
Statistical analysis of peptide abundances in the serum sample cohorts of the DASP verification set (100 healthy control (HC) and 50 T1D subjects), DASP blind set (10 HC and 
10 T1D), and T2D set (50 T2D). Relative peptide abundances were used in the analysis and were represented by peak area ratios of the endogenous peptides to their heavy 
isotope–labeled synthetic analogues. For the DASP verification and blind validation cohorts, fold change was calculated as the ratio of mean of T1D to that of HC within the 
respective cohort. For the T2D specificity cohort, fold change was calculated both as the ratio of mean of T1D to that of T2D and as the ratio of mean of T2D to that of HC of 
the DASP blind set. Mann-Whitney U tests were carried out in DAnTE, while AUCs were calculated with the ROC toolbox in SigmaPlot. The peptide abundance cut-off values at 
AS90 were used to identify the blind samples. The assay specificity and sensitivity were calculated after unblinding the clinical status of the DASP blind set samples. FC, fold 
change; NM, not measured in these samples.
aT1D in respect to HC.
bT1D of blind set in respect to T2D.
cT2D in respect to HC of blind set.
Table 1. (Continued)
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Figure 3. Performance of peptide assay 
NIQSLEVIGK in the DASP verification co-
hort (healthy control, n = 100; T1D,  
n = 50). (A) Box–Whisker plots show the entire 
range of relative peptide abundances in control 
and type 1 diabetic groups, with the lower and 
upper lines of each box representing the 25th 
and 75th percentiles, respectively. The black 
and dotted horizontal lines within each box 
represent the median and mean values, respec-
tively. The crossbars extend to the 10th and 
90th percentile values, with outliers beyond 
this range shown as individual points. Relative 
peptide abundance (y axis) was calculated as 
the ratio between this peptide digested from 
endogenous proteins and its spiked-in, heavy 
isotope–labeled synthetic analogue. (B) ROC 
curve analysis of this peptide in the verification 
sample cohort. The AUC is represented by the  
A value. The higher the A value (1.0 is the maxi-
mum), the better the sensitivity and specificity 
of the peptide assay.
Figure 4. Dot plot showing relative peptide abundance distribu-
tions and gaps between healthy control (n = 10) and T1D patient  
(n = 10) groups, as measured from the independent blind DASP set 
after revealing of clinical status. Red lines represent the individual 
AS90 values that were calculated from the verification DASP cohort, 
which were used as thresholds to identify the blind samples. Only five 
peptides are shown, with peptide NIQSLEVIGK from PPBP and the remain-
ing four peptides from C1 inhibitor (SERPING1).
showed that their levels of peptide NIQSLEVIGK are either 
above or slightly below the mean of this peptide in the dia-
betic group. Conversely, some of the control subjects with 
high positivities of GAD autoantibody assay had very low lev-
els of this peptide. This indicates that the peptide biomarkers 
Based on the level of fibrinogen measured by a sand-
wiched micro-ELISA assay (Gonzalez et al., 2011), a majority 
of the samples in the DASP verification set are sera, whereas 
a few are plasma (Table S2). In addition, there were eight 
T1D samples collected using plasmapheresis procedures, and 
our ELISA assay showed them to be plasma. These plasma-
pheresis samples correlate poorly (Fig. 2) with the rest of the 
diabetic subjects, possibly because of the low total protein 
concentrations for these samples (55.5 ± 18.2 µg/µl) com-
pared with that of the rest of the group (85.5 ± 20.0 µg/µl). 
Except for these eight samples, the sample type (serum or 
plasma) doesn’t affect the performance of our peptide assays. 
For the outliers that we identified from the control or dia-
betic subjects, as revealed by PLS and correlation plot analy-
ses (Fig. 2), the abundances of the target peptides in these 
samples do not correlate with race, age (Fig. 7), and gender, 
or with protein concentrations as measured by bicinchoninic 
acid (BCA) assay (Table S2).
Currently, levels of GAD, IA-2, and insulin autoantibodies 
are the best markers for prediction and diagnosis of T1D 
(Törn et al., 2008; Bingley et al., 2010; Schlosser et al., 2010); 
however, it has been reported that people with high levels of 
these autoantibodies do not always progress to a diabetic state 
(Bingley et al., 1997; Barker et al., 2004; Siljander et al., 
2007). In general, for the samples in our study, diagnosis of 
diabetes correlates to the number of autoantibodies deemed 
positive, but there are some control subjects with high posi-
tivities of at least one of the three autoantibodies, whereas the 
autoantibody levels of two type 1 diabetic subjects were 
called negative by most of the DASP laboratories (Table S2). 
Notably, our peptide assay results can be independent of the 
positivities of the autoantibody assays. For the two diabetic 
subjects having very negative autoantibody levels, our results 
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blind set, whereas NIQSLEVIGK (aa 76–85) showed a 
dramatic 8.5-fold (23-fold if outlier samples had been ex-
cluded from the statistical analysis) up-regulation in the 
DASP verification set and 30-fold up-regulation in the 
blind set (Table 1). Because EESLDSDLYAELR exists ex-
clusively in two forms of CTAPIII, TC-2 and -TG, 
whereas NIQSLEVIGK exists in all four of these proteins, 
in addition to TC-1 and the five forms of NAP-2 (Fig. 8), 
we reason that TC-1/NAP-2s are the major sources of this 
latter peptide. TC-1 is an antibacterial protein released 
from activated platelet -granules as part of the innate im-
mune response (Krijgsveld et al., 2000), whereas the NAP-2s 
are activators of neutrophils and can be generated from 
proteolytic cleavage of both CTAPIII and PPBP by tissue 
proteases (Walz and Baggiolini, 1990). Our results also showed 
that these two peptides were significantly up-regulated in 
sera of T2D subjects when compared with healthy con-
trols, but their levels in T2D subjects were not dramati-
cally different than those found in type 1 diabetic individuals 
(Table 1). Procoagulant and proinflammatory conditions 
deriving from increased platelet adhesiveness have been re-
ported in T1D (Targher et al., 2011). In addition, genomic 
analysis of autoimmune thyroid disease and latent autoimmune 
diabetes of adults identified the PPBP gene CXCL7 to be overly 
expressed in monocytes (van der Heul-Nieuwenhuijsen 
et al., 2010). The general overexpression and differential 
expression of these two peptides in diabetes warrants fur-
ther study to delineate the original isoform of these pep-
tides and to investigate their role in the pathogenesis 
of T1D.
We identified plasma protease C1 inhibitor (SERPING1) 
as a sensitive marker for diagnosing T1D, as its level was sig-
nificantly up-regulated in respect to healthy controls, and 
down-regulated in T2D. C1 inhibitor is known to regulate 
the activation of C1 complex and inhibit chymotrypsin and 
kallikrein, and it may play a crucial role in blood coagula-
tion, fibrinolysis, and suppression of inflammation (Davis 
et al., 2008; Stoermer and Morrison, 2011). Alternatively, 
C1 inhibitor can be used by bacteria against complement-
mediated lysis through binding to bacterial cell membranes 
(Lathem et al., 2004). The mechanism of up-regulation of 
C1 inhibitor and its role in the pathogenesis of T1D remains 
to be investigated. In addition to C1 inhibitor, other prote-
ase inhibitors, such as heparin cofactor (SERPIND1) and 
kininogen-1 (KNG1) were down-regulated consistently in 
T1D, but up-regulated in T2D.
identified in our study are not absolutely dependent on the 
widely accepted autoantibody markers.
The specificity evaluation using samples from individuals 
with T2D demonstrated that most of the peptide markers 
differentiating T1D patients from healthy controls in the 
DASP validation cohort appear to be specific only to T1D. 
Furthermore, although patient levels of HbA1c are not avail-
able from the DASP, our analysis of the relationship between 
HbA1c levels in the T2D samples and the best performing 
peptide markers didn’t show a correlation (Fig. 6). However, 
the potential association between glycemia and these protein 
markers still needs to be determined, particularly in a pro-
spective cohort during the period of gradually increasing gly-
cemia that precedes the diagnosis of T1D.
In its mature form, PPBP precursor can be proteo-
lytically cleaved into 10 polypeptide chains with different 
functions (UniProt accession no. P02775; Fig. 8).  The two 
peptides that were selected to represent PPBP have sharp 
differences in the level of up-regulation in type 1 diabetic 
subjects, with EESLDSDLYAELR (aa 50–62) only having a 
modest 1.6-fold increase in both the DASP verification and 
Table 2. Sample size and age distribution of the subjects in all study cohorts
Sample cohort Sample size Average age (years) Age range (min–max)
DASP_Healthy Controls 100 20.7 18–28
DASP_T1D 50 19.4 10–29
DASP_Blind_Healthy Controls 10 19.6 18–23
DASP_Blind_T1D 10 10.8 5–15
T2D 50 14.4 10.5–18.0
Figure 5. Dot plot showing relative peptide abundance distribu-
tions from all of the samples measured in this study for peptide 
FQPTLLTLPR of C1 inhibitor (SERPING1). DASP cohort: n = 100 for 
healthy control, n = 50 for T1D; independent DASP blind cohort: n = 10 
for healthy control, n = 10 for T1D; T2D cohort: n = 50. Horizontal line, 
mean value; *, P < 0.001.
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pancreatitis (Lasztity et al., 2002) and is involved in the 
development of  cell failure/destruction in T1D (Refai 
et al., 2005).
The proteins we identified are known to play a role in the 
innate immune response, complement activation cascade, in-
flammatory response, and blood coagulation. Given this iden-
tification, their potential role in these physiological processes, 
as well as their contribution to the development of T1D, war-
rant further mechanistic investigation. Such investigations are 
also important, as none of these proteins have direct overlap 
with genetic susceptibility loci identified from the genome-
wide association studies in T1D (Todd et al., 2007). Associa-
tions between altered innate immune responses have been 
shown by others in functional genomics studies (Wang et al., 
2008), specifically of up-regulated proinflammatory factors 
using PBMCs and sera of type 1 diabetic subjects. Although 
the list of proteins that we identified did not exactly match the 
gene list in Wang et al. (2008; and our serum samples are not 
suitable for mRNA measurements), we note that some pro-
teins identified in our study, such as PPBP (CXCL7) and 
Several proteases(BTD, C1R, C2, CNDP1, F2, KLKB1, 
and PGLYRP2) showed differential regulation in type 1 ver-
sus T2D. As an example, human peptidoglycan recognition 
protein 2 (PGLYRP2), an innate immunity protein, is an 
N-acetylmuramoyl-l-alanine amidase that hydrolyzes bacte-
rial peptidoglycan, which is constitutively produced in the 
liver and secreted into the blood, and also induced by bacteria 
in epithelial cells (Dziarski and Gupta, 2006). It was suggested 
that this amidase eliminates proinflammatory peptidoglycan 
and thus prevents overactivation of the immune system lead-
ing to excessive inflammation (Hoijer et al., 1997). In con-
trast, glutathione peroxidase 3 (GPX3) showed similar levels 
of down-regulation in both types of diabetes. With its role in 
protection of cells and enzymes from oxidative damage, its 
down-regulation reflects the body’s reduced capability in 
modulating oxidative stress that commonly occurs in dia-
betes/hyperglycemia. Other proteins that were consistently 
down-regulated in both type 1 and 2 diabetes include gelso-
lin (GSN) and transthyretin (TTR). Interestingly, transthy-
retin has been reported to have decreased levels in chronic 
Figure 6. Plot of abundance of peptides from  
PPBP and C1 inhibitor (SERPING1) in respect to 
each subject’s HbA1c levels in the type 2 diabetic 
sample cohort (n = 50). Peptide NIQSLEVIGK is from 
PPBP and the remaining four peptides from  
C1 inhibitor (SERPING1).
Figure 7. Plot showing that abundance of peptide NIQSLEVIGK of PPBP is independent of subject age in the verification DASP cohort  
(100 healthy control and 50 T1D subjects). (A) 100 healthy control subjects. (B) 50 T1D subjects.
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assays that we have developed provide an efficient approach 
to validate our findings in other large-scale, well-characterized 
population cohorts, as well as in future efforts to evaluate the 
significance of these peptides in predicting T1D progression 
and to unravel the roles of these proteins in the pathogenesis 
of T1D using natural history repository samples.
MATERIALS AND METHODS
Chemicals and materials. All chemicals and peptide-desalting solid phase 
extraction cartridges (Supelco Discovery DSC-18) were purchased from 
Sigma-Aldrich, and the Micro-BCA protein assay kit was obtained 
from Thermo Fisher Scientific. Sequencing-grade trypsin was purchased 
from Promega. All solvents used were LC-grade or higher. SIS peptides with 
uniformly [13C]- and [15N]-labeled arginine or lysine residues on C termini 
and carbamidomethyl modification of cysteine residues were custom synthe-
sized by Thermo Fisher Scientific at the purity level of AQUA Basic (Purity 
>95%). The SIS peptides were received lyophilized and used as is without 
further purification. The amount of each SIS peptide was determined by the 
manufacturer before lyophilization.
Human serum and plasma samples. Human serum and plasma samples 
for discovery, verification, and validation analyses were provided by the 
DASP program, in accordance with the Human Subjects policies and regula-
tions of the United States Centers for Disease Control and Prevention. The 
DASP samples were anonymous and without donor identities. The samples 
for verification corresponded to 100 healthy control individuals and 50 
patients diagnosed with T1D, with mixed ethnicities and genders in each 
group (Table S2). An additional 20 blind samples that were independent to 
the verification cohort were also provided by the DASP to validate the initial 
findings. Patient samples were collected worldwide and were taken from do-
nors within 14 d of their starting insulin treatment. Healthy control samples 
were from individuals who self-reported no diabetes in themselves or their 
families. The blind samples were not decoded to the investigators until data 
analysis was complete and results were reported to the DASP (Table S3). For 
evaluation of the specificity of these markers to diabetes-induced hyperglyce-
mia, serum samples from 50 age-similar, islet autoantibodynegative individu-
als with clinically confirmed T2D were obtained from the University of 
Colorado Denver (Table S4), and were previously collected under the approval 
of the University of Colorado’s Institutional Review Board (IRB). Similarly, all 
work reported here was approved by the IRB of the Pacific Northwest 
National Laboratory. All samples were received frozen on dry ice.
Peptide identification and construction of the AMT tag database. 
The AMT tag approach (Zimmer et al., 2006; Metz et al., 2008) was used in 
quantitative proteomic analyses to discover peptide/protein markers of T1D. 
SERPING1, are from the same gene families as those reported in 
previous studies (i.e., CXCL1, CXCL3, CXCL5, SERPINB2, 
SERPINB8). It should also be noted that gene regulation 
and protein abundance have more complicated relationships. 
In this respect, Vogel and Marcotte (2012) reported that regu-
latory processes after production of mRNAs (i.e., posttran-
scriptional, translational, and protein degradation regulation) 
play substantial roles in controlling steady-state protein abun-
dances. Therefore, transcript abundances are not proxies for 
the concentration and activities of proteins.
In respect to the potential site of their origin (i.e., pro-
duction), most of the proteins identified in our study are 
known to be secreted from the liver. Considering the (appar-
ently) limited inflammation in the pancreatic insulitis of T1D, 
we reason that the abundance of these proteins likely reflect 
more of a secondary or systemic immune response to the 
pathology of T1D, although we cannot rule out that some 
proteins are a result of insulitis. If our belief is correct, one 
might presume it the time for maximal production in T1D, 
as it has been suggested that the peak of insulitis occurs at or 
near the onset of disease (In’t Veld, 2011). To answer this 
question, and to address the important issue regarding the 
predictive value of these serum proteins for T1D prediction, 
in the future the abundances of these proteins in serum will 
be monitored using samples from the natural history studies 
of T1D (i.e., both before and long after disease onset).
To our knowledge, this is the first report that systemic, 
proteome-level dysregulation of the innate immune response 
is a characteristic of T1D, which sheds new light on the 
pathogenesis of this disease and may point to new strategies in 
diagnosis, intervention, and prevention. Importantly, some 
of these surrogate peptide markers are independent of the 
commonly used autoantibody assays for diagnosis of T1D, 
and are specific to only individuals with this disease, and not 
diabetes-induced hyperglycemia in general. Collectively, our 
results demonstrate the power of LC-MS–based proteomics 
technologies in the discovery and validation of peptide 
markers of T1D from human serum and plasma. Although 
the proteins we have identified have little overlap with those 
discovered by Zhi et al. (2011), the LC-MRM-MS peptide 
Figure 8. Sequence alignment of the two peptides representing PPBP, with the start and end amino acids labeled in the sequence. 
NIQSLEVIGK exists in all protein isoforms, whereas EESLDSDLYAELR exists exclusively in two forms of CTAPIII, and in TC-2 and -TG.
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of ±3 ppm and ±0.02 NET for monoisotopic mass and elution time, respec-
tively. This peak-matching process gave an initial list of peptide identifica-
tions for each individual dataset; in addition, all peptides were required to be 
observed in at least 50% of LC-FTICR-MS datasets in each disease state.
DAnTE (Polpitiya et al., 2008) was then used for quantitative and statis-
tical analysis of the identified peptide abundances. In brief, the matrix of 
peptide abundances from all LC-FTICR-MS analyses were log2 trans-
formed, and then normalized globally using a central tendency algorithm 
(Callister et al., 2006) to variations in the data caused by amount of sample 
loaded onto the LC column and peptide ionization efficiency. For each pep-
tide, a Student’s t test was performed between the samples in the control and 
patient groups, and only peptides with p-values <0.05 were considered as 
significantly changed. To facilitate visualization of quantitative changes in 
peptide abundances across all 20 samples, the data were Z-score transformed 
before loading in the open-source tool TIGR Multiexperiment Viewer 
(Saeed et al., 2006). Functional annotation of these proteins were performed 
on line using DAVID (Huang et al., 2009).
Selection of peptide targets for MRM verification. The processing and 
analysis of the global quantitative proteomics data resulted in the identification 
of 24 candidate protein biomarkers of T1D, the peptides of which were 
screened to remove those with the following characteristics: (a) nontryptic; (b) 
greater than 20 aa long; (c) shorter than 7 aa; and (c) containing methionine 
(Kuzyk et al., 2009). In addition, an attempt was made to remove peptides that 
contained cysteine or other known posttranslational modification sites. The 
best-scoring tandem mass spectra for each peptide identified in the global pro-
teomics data were manually reviewed using Mass Analyzer (Zhang, 2004), and 
the peptide sequence fragmentation modeling tool in Molecular Weight Cal-
culator to select the precursor and associated top six most intense fragment ions 
(i.e., MRM transitions). A tryptic digest (0.4 µg/µl) of a pooled serum sample 
from healthy subjects was used to screen for the detectabilities and specificities 
(i.e., whether there are other peptides sharing the same MRM transitions that 
co-elute with the target peptides) of these transitions in a complex matrix using 
our LC-MRM-MS platform. The collision energies (CE) used to fragment 
each precursor were calculated from the following equations: for 2+ precur-
sors, CE = 0.034 m/z + 3.314 and for 3+ precursors, CE = 0.044 m/z + 
3.314, where m/z is the mass/charge value of the precursor (Maclean et al., 
2010a). Only those peptides having relatively high s/n and few matrix interfer-
ences were retained for the next round of screening. After two additional rounds 
of screening, including the removal of peptides with poor LC-MRM-MS 
performance, all remaining peptides showed good detectability and specificity. 
The stable isotope-labeled versions of these peptides were then synthesized and 
used for establishing the final LC-MRM-MS assays and for spiking into each 
sample for verification of candidate biomarkers.
LC-MRM-MS assay set-up. Because the SIS and endogenous peptides 
co-elute on the LC column and have the same ionization efficiency and 
fragmentation behavior under collision-induced dissociation, we used the 
SIS peptides to optimize the detection parameters of the endogenous pep-
tides. In brief, the synthetic SIS peptides were individually dissolved in 0.1% 
formic acid/CH3CN (50:50, vol/vol) and then infused to a triple quadru-
pole mass spectrometer (TSQ; Thermo Fisher Scientific) to optimize their 
collision energies and to verify their MRM transitions selected during the 
screening process. The SIS peptides were then individually spiked into 
serum tryptic digests, and through isotope dilution experiments using 
LC-MRM-MS, their retention times and best single MRM transitions were 
determined for use in the final assay. The retention time information from 
all peptides was used to set up a segmented MRM-MS method, such that all 
peptide targets could be monitored in the final multiplexed LC-MRM-MS 
assay (Table S1). The linear dynamic ranges of the SIS peptides were also 
determined in these measurements.
Preparation of concentration-balanced SIS peptide mixture. Because 
of the large variations in endogenous levels of each peptide, their different 
ionization efficiencies and different linear dynamic ranges in quantification, 
In brief, aliquots of each control or patient serum/plasma sample (n = 50 
each) were pooled, and the pooled samples were then subjected to immuno-
affinity subtraction using a SuperMix LC2 immunodepletion system (Sigma-
Aldrich) coupled with an Agilent 1100 series HPLC, as described previously 
(Qian et al., 2008). The flow-through fractions (low abundance proteins) 
were collected, pooled, and then concentrated in Amicon Ultra-15 concen-
trators (Millipore) with MWCO of 3 kD, followed by a buffer exchange to 
50 mM NH4HCO3 in the same unit, according to the manufacturer’s in-
structions. As reported previously, sample proteins were next sequentially 
denatured, reduced, alkylated, and digested with trypsin; the peptide mix-
tures were then cleaned with C18 SPE cartridges and fractionated using 
strong cation exchange chromatography (Metz et al., 2008). A total of 30 
peptide fractions were collected and analyzed in duplicate using a custom-
built 4-column nanocapillary LC system coupled online to a linear ion-trap 
mass spectrometer (LTQ; Thermo Fisher Scientific). Peptides were sepa-
rated on capillary columns (75 µm × 65 cm) packed in-house with 3-µm 
Jupiter C18 particles (Phenomenex; Qian et al., 2008). The LTQ was oper-
ated in data-dependent MS/MS mode, during which a full MS scan was fol-
lowed by 10 MS/MS scan events.
The SEQUEST search algorithm was used to match the MS/MS frag-
mentation spectra with sequences from the IPI human protein database 
(Version 3.39); static carbamidomethylation of cysteine and dynamic oxida-
tion of methionine were used for the database search. Database-matched re-
sults were filtered using criteria based on the cross correlation score (Xcorr), 
 correlation (Cn) values, trypsin cleavage rules, and charge states to limit 
false positive identifications to 1% at the peptide level using the decoy da-
tabase approach (Metz et al., 2008). Peptides passing these filter criteria were 
added to the AMT tag database. The final plasma AMT tag database con-
tained 18,157 human plasma peptides available for matching to subsequent 
high-resolution LC-MS datasets (see following paragraph), which include 
data from a previous proteomics study of a DASP sample subset (Metz et al., 
2008) and several other studies. The peptide elution times from each 
LC-MS/MS analysis were normalized to a range of 0 to 1 using a predictive 
normalized elution time (NET) model (Petritis et al., 2006). Both calculated 
monoisotopic masses and observed NETs of identified peptides were in-
cluded in the AMT tag database.
Quantitative global proteomics analyses. Aliquots of each individual 
control and patient serum/plasma sample were pooled to form 10 pooled 
control and 10 pooled patient samples, with samples from 5 individuals com-
prising each pool. Each pooled sample was subjected to immunoaffinity sub-
traction of abundant proteins using the SuperMix immunodepletion system, 
as described in the previous section, with the exception that both the flow-
through (low abundance proteins) and bound (high abundance proteins) 
fractions were collected separately and subjected to tryptic digestion and 
clean-up, as described above. Peptides from each pooled sample were then 
analyzed in duplicate using the same nanocapillary LC system described 
above, which was coupled to a 9.4 Tesla Fourier transform ion cyclotron 
resonance-mass spectrometry (FTICR-MS; Bruker Daltonics) set to only 
collect high-resolution MS data.
LC-FTICR-MS datasets were processed using the PRISM Data Analy-
sis system (Kiebel et al., 2006), a series of software tools (e.g., Decon2LS, 
VIPER; freely available at http://ncrr.pnl.gov/software/) developed in-
house. Decon2LS functions to deisotope the raw MS data, providing the 
monoisotopic mass, charge state, and intensity of the major peaks in each MS 
spectrum. The data were then examined in a 2D fashion to identify “fea-
tures” using VIPER; each feature has a median monoisotopic mass, central 
NET, and abundance estimate computed by adding up the intensities of the 
MS peaks that comprise the entire LC-FTICR-MS feature. To facilitate 
identification and quantification across multiple datasets, the detected fea-
tures in each dataset (referring to data from a single LC-FTICR-MS analysis) 
were aligned against the peptides within the AMT tag database using the 
LCMSWARP algorithm. This is accomplished by comparing the measured 
monoisotopic masses and NETs of the detected features to the calculated 
ones of each of the peptides in the AMT tag database within search tolerances 
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peptide assay in discriminating disease from control. The AUC with 95% 
Confidence Interval was calculated assuming a nonparametric distribution. 
An AUC of 1.00 would indicate the peptide achieved 100% accuracy in 
identifying disease, and an AUC of 0.50 would indicate that the assignment 
of disease/control is entirely random. To facilitate the identification of sam-
ples in the blind group, the cut-off value of peak area ratio corresponding to 
sensitivity at 90% specificity (AS90) was obtained from the sensitivity and 
specificity report of ROC curve analysis for each peptide, and it was used as 
a threshold to classify the blind samples into control and disease. Then the 
sensitivity for each peptide assay was calculated as the percentage of sera from 
patients in the blind samples reported as positive using the individual cut-off 
values at AS90, and the specificity of each peptide assay was calculated as the 
percentage of control sera reported as negative using the same threshold. 
Calculation of the endogenous concentration of each peptide/protein was 
based on the amount of SIS peptide spiked and the average peak area ratio as 
measured in endogenous/SIS peptide.
Online supplemental material. Table S1 shows the detailed param-
eters for the 52 peptide LC-MRM-MS assays. Tables S2–S4 show the 
clinical data for the DASP verification, blind set, and T2D cohorts, re-
spectively. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20111843/DC1.
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